Report cover image

Global Biologics CDMO Market 2023-2027

Publisher TechNavio
Published Feb 02, 2023
Length 158 Pages
SKU # INF17761532

Description

Global Biologics CDMO Market 2023-2027

Technavio has been monitoring the biologics CDMO market and is forecast to grow by $13.26 bn during 2022-2027, accelerating at a CAGR of 13.97% during the forecast period. Our report on the biologics CDMO market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the availability of cost-efficient resources in emerging markets, strong research and development pipeline of biologics therapeutics, and a growing need to focus on core competencies.

Technavio's biologics CDMO market is segmented as below:

By Type
  • Mammalian
  • Microbial
By Product Type
  • Biologics
  • Biosimilars
By Geography
  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the advent of big data as one of the prime reasons driving the biologics CDMO market growth during the next few years. Also, strategic alliances and partnerships with pharma companies and increasing approvals for new molecules and biosimilars will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the biologics CDMO market covers the following areas:
  • Biologics CDMO market sizing
  • Biologics CDMO market forecast
  • Biologics CDMO market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biologics CDMO market vendors that include 3P BIOPHARMACEUTICALS S.L.U., AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals Co. Ltd., Catalent Inc., Cytovance Biologics, Evonik Industries AG, FUJIFILM Holdings Corp, Grifols SA, JRS PHARMA GmbH and Co. KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., KLOCKE GROUP, Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc. Also, the biologics CDMO market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

158 Pages
    • Market overview
    • Market ecosystem
    • Market definition
    • Market segment analysis
    • Market size 2022
    • Market outlook: Forecast for 2022-2027
    • Global biologics CDMO market 2017 - 2021
    • Type Segment Analysis 2017 - 2021
    • Product type Segment Analysis 2017 - 2021
    • Geography Segment Analysis 2017 - 2021
    • Country Segment Analysis 2017 - 2021
    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
    • Market segments
    • Comparison by Type
    • Mammalian - Market size and forecast 2022-2027
    • Microbial - Market size and forecast 2022-2027
    • Market opportunity by Type
    • Market segments
    • Comparison by Product Type
    • Biologics - Market size and forecast 2022-2027
    • Biosimilars - Market size and forecast 2022-2027
    • Market opportunity by Product Type
    • Customer landscape overview
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2022-2027
    • Europe - Market size and forecast 2022-2027
    • Asia - Market size and forecast 2022-2027
    • Rest of World (ROW) - Market size and forecast 2022- 2027
    • US - Market size and forecast 2022-2027
    • China - Market size and forecast 2022-2027
    • Germany - Market size and forecast 2022-2027
    • France - Market size and forecast 2022-2027
    • Japan - Market size and forecast 2022-2027
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Impact of drivers and challenges
    • Market trends
    • Overview
    • Vendor landscape
    • Landscape disruption
    • Industry risks
    • Vendors covered
    • Market positioning of vendors
    • AbbVie Inc.
    • Binex Co. Ltd.
    • Boehringer Ingelheim International GmbH
    • Bora Pharmaceuticals Co. Ltd.
    • Catalent Inc.
    • Evonik Industries AG
    • FUJIFILM Holdings Corp
    • Grifols SA
    • JRS PHARMA GmbH and Co. KG
    • Lonza Group Ltd.
    • Novartis AG
    • Rentschler Biopharma SE
    • Samsung Biologics Co. Ltd.
    • Toyobo Co. Ltd.
    • WuXi Biologics Cayman Inc.
    • Scope of the report
    • Inclusions and exclusions checklist
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us